Skip to main navigation Skip to search Skip to main content

A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma

  • Jacob P. Laubach
  • , Noopur S. Raje
  • , Andrew J. Yee
  • , Philippe Armand
  • , Robert L. Schlossman
  • , Jacalyn Rosenblatt
  • , Jeffrey Matous
  • , Jacquelyn Hedlund
  • , Michael G Martin
  • , Craig Reynolds
  • , Kenneth H. Shain
  • , Ira Zackon
  • , Laura V. Stampleman
  • , Erica N Boswell
  • , Stacey Chuma
  • , Rebecca Liguori
  • , Stephanie Mar
  • , Damian Handisides
  • , Stew Kroll
  • , Kenneth C. Anderson
  • Paul G. Richardson, Irene M. Ghobrial
  • Harvard University
  • Beth Israel Deaconess Medical Center
  • Blood Cancer Research Partnership, Boston, MA
  • New England Cancer Specialisits, Scarborough, ME
  • University of Tennessee Health Science Center
  • Ocala Oncology Center, Ocala, FL
  • H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
  • New York Oncology Hematology, Albany, NY
  • Pacific Care Center, Salinas, CA
  • Threshold Pharmaceuticals, Inc., South San Francisco, CA

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalBlood
Volume124
Issue number21
DOIs
StatePublished - Dec 6 2014
Externally publishedYes

Disciplines

  • Medicine and Health Sciences
  • Gastroenterology
  • Internal Medicine

Cite this